2565656-71-3
Chemical Structure
Muvalaplin tetrahydrochloride
Synonym(s): LY3473329 tetrahydrochloride
- CAS No.: 2565656-71-3
- Formula:C42H58Cl4N4O6
- Molecular Weight:856.75
IUPAC Name: 4-(4-(4-methylnaphthalen-1-yl)pyridin-3-yl)benzene-1,2-diol
InChIKey: AUDVDLFTWNDUJS-NISFFQGWSA-N
SMILES: OC([C@H]([C@H]1CCNC1)CC2=CC(CN(CC3=CC(C[C@@H]([C@H]4CCNC4)C(O)=O)=CC=C3)CC5=CC(C[C@@H]([C@H]6CCNC6)C(O)=O)=CC=C5)=CC=C2)=O.[H]Cl.[H]Cl.[H]Cl.[H]Cl
Biological Activity: Muvalaplin tetrahydrochloride (LY3473329 tetrahydrochloride) is an orally active small molecule apolipoprotein a (apolipoprotein a) inhibitor that binds to the KIV8 domain (Kd = 22 nM) and kringle IV domains 7 and 8, blocks the non-covalent interaction between apo (a) and apoB-100, and prevents Lp (a) assembly, thereby lowering circulating Lp (a) levels. Muvalaplin tetrahydrochloride can be used in research on atherosclerotic cardiovascular disease[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Muvalaplin tetrahydrochloride | 99.55% | Muvalaplin tetrahydrochloride (LY3473329 tetrahydrochloride) is an orally active small molecule apolipoprotein a (apolipoprotein a) inhibitor that binds to the KIV8 domain (Kd = 22 nM) and kringle IV domains 7 and 8, blocks the non-covalent interaction between apo (a) and apoB-100, and prevents Lp (a) assembly, thereby lowering circulating Lp (a) levels. Muvalaplin tetrahydrochloride can be used in research on atherosclerotic cardiovascular disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vuorio A. Promising results with the daily oral small molecule lipoprotein (a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein (a) levels. Annals of translational medicine. 2025 Apr 29;13(2):11.
- [2]. Nicholls SJ, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023 Sep 19;330(11):1042-1053. [Content Brief]
- [3]. Diaz N, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024 May;629(8013):945-950. [Content Brief]
- [4]. Nicholls SJ, et al. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280.
- [5]. Leake I. A route to small-molecule Lp(a) inhibitors for heart disease. Nat Rev Drug Discov. 2024 Jul;23(7):498.
